Open AccessHuman Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Author(s) -
Wendy Painter,
Wayne Holman,
Jim Bush,
Firas Almazedi,
Hamzah Malik,
Nicola C. J. E. Eraut,
Merribeth J. Morin,
Laura J Szewczyk,
George R. Painter
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02428-20
Subject(s) - pharmacokinetics , adverse effect , medicine , tolerability , placebo , pharmacology , rash , gastroenterology , pathology , alternative medicine
Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral ribonucleoside analog β- d -N4-hydroxycytidine (NHC; EIDD-1931), has activity against a number of RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and seasonal and pandemic influenza viruses. Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.